437 related articles for article (PubMed ID: 17305535)
21. Chemistry of silybin.
Biedermann D; Vavříková E; Cvak L; Křen V
Nat Prod Rep; 2014 Sep; 31(9):1138-57. PubMed ID: 24977260
[TBL] [Abstract][Full Text] [Related]
22. Extraction, Chemical Composition, Antioxidant Property, and In-vitro Anticancer Activity of Silymarin from Silybum marianum on Kb and A549 Cell Lines.
Azadpour M; Farajollahi MM; Varzi AM; Hashemzadeh P; Mahmoudvand H; Barati M
Curr Drug Discov Technol; 2021; 18(4):511-517. PubMed ID: 32860361
[TBL] [Abstract][Full Text] [Related]
23. Spatial organization of silybin biosynthesis in milk thistle [Silybum marianum (L.) Gaertn].
Lv Y; Gao S; Xu S; Du G; Zhou J; Chen J
Plant J; 2017 Dec; 92(6):995-1004. PubMed ID: 28990236
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.
Ting H; Deep G; Agarwal R
AAPS J; 2013 Jul; 15(3):707-16. PubMed ID: 23588585
[TBL] [Abstract][Full Text] [Related]
25. Milk thistle in liver diseases: past, present, future.
Abenavoli L; Capasso R; Milic N; Capasso F
Phytother Res; 2010 Oct; 24(10):1423-32. PubMed ID: 20564545
[TBL] [Abstract][Full Text] [Related]
26. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
Mastron JK; Siveen KS; Sethi G; Bishayee A
Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
[TBL] [Abstract][Full Text] [Related]
27. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
Feng N; Luo J; Guo X
Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
[TBL] [Abstract][Full Text] [Related]
28. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
Flaig TW; Gustafson DL; Su LJ; Zirrolli JA; Crighton F; Harrison GS; Pierson AS; Agarwal R; Glodé LM
Invest New Drugs; 2007 Apr; 25(2):139-46. PubMed ID: 17077998
[TBL] [Abstract][Full Text] [Related]
29. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats.
Krecman V; Skottová N; Walterová D; Ulrichová J; Simánek V
Planta Med; 1998 Mar; 64(2):138-42. PubMed ID: 9525106
[TBL] [Abstract][Full Text] [Related]
30. Chemopreventive efficacy of silymarin in skin and prostate cancer.
Deep G; Agarwal R
Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
[TBL] [Abstract][Full Text] [Related]
31. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Ou Q; Weng Y; Wang S; Zhao Y; Zhang F; Zhou J; Wu X
Dig Dis Sci; 2018 Dec; 63(12):3398-3408. PubMed ID: 30191499
[TBL] [Abstract][Full Text] [Related]
32. [Flavonolignans - compounds not only for liver treatment].
Bijak M
Pol Merkur Lekarski; 2017 Jan; 42(247):34-37. PubMed ID: 28134230
[TBL] [Abstract][Full Text] [Related]
33. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
[TBL] [Abstract][Full Text] [Related]
34. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.
Pradhan SC; Girish C
Indian J Med Res; 2006 Nov; 124(5):491-504. PubMed ID: 17213517
[TBL] [Abstract][Full Text] [Related]
35. Identification of hepatoprotective flavonolignans from silymarin.
Polyak SJ; Morishima C; Lohmann V; Pal S; Lee DY; Liu Y; Graf TN; Oberlies NH
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5995-9. PubMed ID: 20231449
[TBL] [Abstract][Full Text] [Related]
36. Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer.
Hosseinabadi T; Lorigooini Z; Tabarzad M; Salehi B; Rodrigues CF; Martins N; Sharifi-Rad J
Phytother Res; 2019 Nov; 33(11):2849-2861. PubMed ID: 31407422
[TBL] [Abstract][Full Text] [Related]
37. [An updated review at molecular pharmacological level for the mechanism of anti-tumor, antioxidant and immunoregulatory action of silibinin].
Wang HJ; Jiang YY; Lu P; Wang Q; Ikejima T
Yao Xue Xue Bao; 2010 Apr; 45(4):413-21. PubMed ID: 21355204
[TBL] [Abstract][Full Text] [Related]
38. Silymarin and its constituents in cardiac preconditioning.
Zholobenko A; Modriansky M
Fitoterapia; 2014 Sep; 97():122-32. PubMed ID: 24879900
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the nanotechnology-based drug delivery of Silybin.
Wang Y; Zhang L; Wang Q; Zhang D
J Biomed Nanotechnol; 2014 Apr; 10(4):543-58. PubMed ID: 24734507
[TBL] [Abstract][Full Text] [Related]
40. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model.
Lahiri-Chatterjee M; Katiyar SK; Mohan RR; Agarwal R
Cancer Res; 1999 Feb; 59(3):622-32. PubMed ID: 9973210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
